Nothing Special   »   [go: up one dir, main page]

SI3576740T1 - Zdravljenje raka - Google Patents

Zdravljenje raka

Info

Publication number
SI3576740T1
SI3576740T1 SI201830961T SI201830961T SI3576740T1 SI 3576740 T1 SI3576740 T1 SI 3576740T1 SI 201830961 T SI201830961 T SI 201830961T SI 201830961 T SI201830961 T SI 201830961T SI 3576740 T1 SI3576740 T1 SI 3576740T1
Authority
SI
Slovenia
Prior art keywords
cancer treatment
cancer
treatment
Prior art date
Application number
SI201830961T
Other languages
English (en)
Inventor
Kim Stuyckens
Ruixo Juan Jose Perez
Porre Peter Marie Z. De
Anjali Narayan Avadhani
Yohann Loriot
Arlene O. Siefker-Radtke
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=61094531&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI3576740(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Priority claimed from PCT/EP2018/052694 external-priority patent/WO2018141921A1/en
Publication of SI3576740T1 publication Critical patent/SI3576740T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Laminated Bodies (AREA)
  • Processing And Handling Of Plastics And Other Materials For Molding In General (AREA)
  • Medicinal Preparation (AREA)
  • Prostheses (AREA)
SI201830961T 2017-02-06 2018-02-02 Zdravljenje raka SI3576740T1 (sl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762455211P 2017-02-06 2017-02-06
EP17209098 2017-12-20
EP18702299.1A EP3576740B1 (en) 2017-02-06 2018-02-02 Cancer treatment
PCT/EP2018/052694 WO2018141921A1 (en) 2017-02-06 2018-02-02 Cancer treatment

Publications (1)

Publication Number Publication Date
SI3576740T1 true SI3576740T1 (sl) 2023-10-30

Family

ID=61094531

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201830961T SI3576740T1 (sl) 2017-02-06 2018-02-02 Zdravljenje raka

Country Status (25)

Country Link
US (2) US11077106B2 (sl)
EP (2) EP3576740B1 (sl)
JP (3) JP2020505425A (sl)
KR (2) KR20190110581A (sl)
CN (1) CN110198716A (sl)
AU (2) AU2018216969B2 (sl)
BR (1) BR112019016043A2 (sl)
CA (1) CA3049737A1 (sl)
DK (1) DK3576740T3 (sl)
ES (1) ES2953005T3 (sl)
FI (1) FI3576740T3 (sl)
HR (1) HRP20230697T1 (sl)
HU (1) HUE062453T2 (sl)
IL (1) IL268463A (sl)
JO (1) JOP20190190A1 (sl)
LT (1) LT3576740T (sl)
MX (2) MX2019009304A (sl)
PH (1) PH12019501885A1 (sl)
PL (1) PL3576740T3 (sl)
RS (1) RS64778B1 (sl)
SG (2) SG11201907199QA (sl)
SI (1) SI3576740T1 (sl)
SM (1) SMT202300233T1 (sl)
TW (1) TWI874925B (sl)
UA (1) UA126336C2 (sl)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20220496T1 (hr) 2014-09-26 2022-05-27 Janssen Pharmaceutica Nv Uporaba fgfr mutantnih genskih panela kod identifikacije pacijenata s rakom koji će reagirati na liječenje s inhibitorom fgfr
US20200208224A1 (en) * 2014-09-26 2020-07-02 Janssen Pharmaceutica Nv Use Of FGFR Mutant Gene Panels In Identifying Cancer Patients That Will Be Responsive To Treatment With An FGFR Inhibitor
JOP20190190A1 (ar) * 2017-02-06 2019-08-04 Janssen Pharmaceutica Nv معالجة سرطان
CN113423402A (zh) * 2019-02-12 2021-09-21 詹森药业有限公司 癌症治疗
CA3130460A1 (en) * 2019-03-29 2020-10-08 Anne Elizabeth O'HAGAN Fgfr tyrosine kinase inhibitors for the treatment of urothelial carcinoma
CA3130773A1 (en) * 2019-03-29 2020-10-08 Peter Marie Z. De Porre Fgfr tyrosine kinase inhibitors for the treatment of urothelial carcinoma
WO2021201201A1 (ja) * 2020-04-03 2021-10-07 インタープロテイン株式会社 新型コロナウイルス感染症（ｃｏｖｉｄ－１９）の予防または治療剤および医薬組成物
TW202508591A (zh) * 2023-05-24 2025-03-01 比利時商健生藥品公司 癌症治療

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20200201A1 (ar) 2015-02-10 2017-06-16 Astex Therapeutics Ltd تركيبات صيدلانية تشتمل على n-(3.5- ثنائي ميثوكسي فينيل)-n'-(1-ميثيل إيثيل)-n-[3-(ميثيل-1h-بيرازول-4-يل) كينوكسالين-6-يل]إيثان-1.2-ثنائي الأمين
US10478494B2 (en) * 2015-04-03 2019-11-19 Astex Therapeutics Ltd FGFR/PD-1 combination therapy for the treatment of cancer
JOP20190190A1 (ar) * 2017-02-06 2019-08-04 Janssen Pharmaceutica Nv معالجة سرطان

Also Published As

Publication number Publication date
UA126336C2 (uk) 2022-09-21
IL268463A (en) 2019-09-26
US11077106B2 (en) 2021-08-03
LT3576740T (lt) 2023-08-10
JP2025024064A (ja) 2025-02-19
RS64778B1 (sr) 2023-11-30
KR20250069693A (ko) 2025-05-19
JP2023022190A (ja) 2023-02-14
BR112019016043A2 (pt) 2020-03-31
MX2022007955A (es) 2022-07-27
SG10202105110VA (en) 2021-06-29
AU2024201871A1 (en) 2024-04-11
US20220110935A1 (en) 2022-04-14
AU2018216969A1 (en) 2019-07-25
US20200022976A1 (en) 2020-01-23
DK3576740T3 (da) 2023-07-24
SMT202300233T1 (it) 2023-09-06
MX2019009304A (es) 2019-09-19
JP2020505425A (ja) 2020-02-20
JP7668777B2 (ja) 2025-04-25
SG11201907199QA (en) 2019-09-27
HRP20230697T1 (hr) 2023-10-13
JOP20190190A1 (ar) 2019-08-04
PL3576740T3 (pl) 2023-09-11
CA3049737A1 (en) 2018-08-09
AU2018216969B2 (en) 2024-04-11
EP4286005A2 (en) 2023-12-06
ES2953005T3 (es) 2023-11-07
CN110198716A (zh) 2019-09-03
EP3576740B1 (en) 2023-06-14
PH12019501885A1 (en) 2020-06-29
FI3576740T3 (fi) 2023-08-31
EP4286005A3 (en) 2024-03-06
EP3576740A1 (en) 2019-12-11
TW202402290A (zh) 2024-01-16
HUE062453T2 (hu) 2023-11-28
TWI874925B (zh) 2025-03-01
KR20190110581A (ko) 2019-09-30

Similar Documents

Publication Publication Date Title
IL269026A (en) Methods of treating tumor
IL255189A0 (en) Methods of treating cancer
EP3651772A4 (en) ANTI-CANCER POLYTHERAPY
RS64787B1 (sr) Lečenje lag-3-pozitivnih tumora
EP3601536A4 (en) TREATMENT PROCESSES
PL3283527T3 (pl) Leczenie skojarzone nowotworów
DK3288581T3 (da) Fremgangsmåde til behandling af cancer
HUE059694T2 (hu) Készítmény rák kezelésére
EP3474854A4 (en) DRUG ASSOCIATIONS FOR THE TREATMENT OF CANCER
IL265697B1 (en) Treatment of prostate cancer
RS61786B1 (sr) Kombinovani tretman za kancer
KR20180084772A (ko) 암 치료를 위한 조합 치료법
IL268463A (en) Cancer treatment
MA47408A (fr) Traitement du cancer
IL264443A (en) Methods of treating prostate cancer
EP3413927A4 (en) CANCER THERAPY
EP3546020A4 (en) CANCER TREATMENT APPARATUS
DK3768830T5 (da) Cancerterapi
HUE040167T2 (hu) Rákkezelés
IL308399A (en) Methods of treating cancer
EP3675891A4 (en) ANTI-CANCER POLYTHERAPY
EP3576791A4 (en) CALRETICULIN-MEDIATION CANCER TREATMENT
IL281600A (en) Methods of treating cancer
IL281845A (en) Combination therapy for the treatment of cancer
EP3597225A4 (en) TREATMENT PROCESS